Lian Xue, Dr. Caitlin V. M. L. Jie, Dr. Sandrine Desrayaud, Dr. Yves P. Auberson
{"title":"Front Cover: Developing Low Molecular Weight PET and SPECT Imaging Agents (ChemMedChem 15/2024)","authors":"Lian Xue, Dr. Caitlin V. M. L. Jie, Dr. Sandrine Desrayaud, Dr. Yves P. Auberson","doi":"10.1002/cmdc.202481501","DOIUrl":null,"url":null,"abstract":"<p>The <b>Front Cover</b> shows the clinical demands that drive the development of novel imaging agents for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Multiple pathways lead from the initial concept to a practically useful compound. The process for the discovery and development of imaging agents follows a well-documented path; however, variations are possible and provide some flexibility depending on the resources and technologies available to the project team. According to the question asked, the properties of the imaging agents will vary, and the requirements for their development will differ. Understanding the target profile required to address the clinical questions, as well as the possible steps enabling the discovery, optimization, and validation of imaging agents is critical. Like when climbing a mountain, resource efficiency and speed should be optimized to guarantee the optimal development of novel imaging agent candidates. More details can be found in article 10.1002/cmdc.202400094 by Yves P. Auberson and co-workers.\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202481501","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202481501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The Front Cover shows the clinical demands that drive the development of novel imaging agents for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Multiple pathways lead from the initial concept to a practically useful compound. The process for the discovery and development of imaging agents follows a well-documented path; however, variations are possible and provide some flexibility depending on the resources and technologies available to the project team. According to the question asked, the properties of the imaging agents will vary, and the requirements for their development will differ. Understanding the target profile required to address the clinical questions, as well as the possible steps enabling the discovery, optimization, and validation of imaging agents is critical. Like when climbing a mountain, resource efficiency and speed should be optimized to guarantee the optimal development of novel imaging agent candidates. More details can be found in article 10.1002/cmdc.202400094 by Yves P. Auberson and co-workers.
封面展示了推动正电子发射断层扫描(PET)或单光子发射计算机断层扫描(SPECT)新型成像剂开发的临床需求。从最初的概念到实际有用的化合物有多种途径。成像剂的发现和开发过程遵循一条有据可查的路径;不过,根据项目团队可用的资源和技术,也有可能出现一些变化,并提供一定的灵活性。根据提出的问题,成像剂的特性会有所不同,对其开发的要求也会不同。了解解决临床问题所需的靶点概况,以及发现、优化和验证成像剂的可能步骤至关重要。就像爬山一样,应优化资源效率和速度,以保证新型成像剂候选物的最佳开发。更多详情,请参阅伊夫-P-奥布森(Yves P. Auberson)及其合作者撰写的文章 10.1002/cmdc.202400094。
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.